Cellectar Biosciences (CLRB) Reports Q1 Loss of $0.30/Share

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/5/2026

1. NVDA
2. SPY
3. PTC
4. META
5. PCVX
6. USO
7. MSFT
8. AMZN
9. AMD
10. ATH

Go back to Cellectar Biosciences (CLRB) Reports Q1 Loss of $0.30/Share

Cellectar Biosciences Reports First Quarter 2015 Financial Results and Provides Update on Clinical Programs

May 21, 2015 4:15 PM EDT

MADISON, Wis., May 21, 2015 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB), a clinical stage biopharmaceutical company developing innovative agents for the detection and treatment of cancer, is providing an update on its development programs and financial results for the first quarter 2015.

Clinical Development Program Updates:

I-124-CLR1404

After activating five large new centers this year, Cellectar has seen an increase in patient screening and anticipates a significant increase in enrollment in its Phase II trial of I-124-CLR1404 in glioblastoma. However, enrollment remains slower than expected and... More

Cellectar Biosciences Reports First Quarter 2015 Financial Results and Provides Update on Clinical Programs

May 21, 2015 4:15 PM EDT

MADISON, Wis., May 21, 2015 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB), a clinical stage biopharmaceutical company developing innovative agents for the detection and treatment of cancer, is providing an update on its development programs and financial results for the first quarter 2015.

Clinical Development Program Updates:

I-124-CLR1404

After activating five large new centers this year, Cellectar has seen an increase in patient screening and anticipates a significant increase in enrollment in its Phase II trial of I-124-CLR1404 in glioblastoma. However, enrollment remains slower than expected and... More